SAKhARNYY DIABET 2 TIPA I NEALKOGOL'NAYa ZhIROVAYa BOLEZN' PEChENI: PRAKTIChESKIE REKOMENDATsII DLYa ENDOKRINOLOGOV


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In clinical practice, type 2 diabetes mellitus (DM2) is often associated with non-alcoholic fatty liver disease (NAFLD), which includes several morphological forms and develops in patients without alcohol abuse. The combination of DM2 and NAFLD is associated not only with a high risk of liver cirrhosis and hepatocellular carcinoma in these patients. The presence of NAFLD in DM2 patients is also a predictor of high cardiovascular risk and increased mortality. Despite the findings on the progressive nature of NAFLD in DM2 patients, treatment of NAFLD in DM2 patients remains unclear.

全文:

受限制的访问

作者简介

A. Ametov

参考

  1. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-19.
  2. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7(8): 456-65.
  3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142 (7):1592-609.
  4. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
  5. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hithertounnamed disease. Mayo Clin Proc 1980;55:434-38.
  6. de Marco R. et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-61.
  7. Targher G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-46.
  8. Schuppan D, Gorrell MD, Klein T, et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010;30(6):795-808.
  9. Liagnpunsakul S, Chalasani N. What do we recommend our patients with NAFLD about alcohol consumption? Am J Gastroenterol 2012l;107(7):976-78.
  10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol 2003;98:960-7.
  11. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol 2007;102: 399-408.
  12. Machado M., Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6.
  13. Marchesini G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
  14. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
  15. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Ann 1989;24:275-302.
  16. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-65.
  17. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006;29:1845-50.
  18. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285,E906-E16.
  19. Banerji M.A, et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846-50.
  20. Targher G, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-9.
  21. Targher G, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-58.
  22. Targher G, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006;29:55-60.
  23. Lautam ki R, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006;291:E282-E90.
  24. Day CP, James OF. Steatohepatitis: a tale of two “hits"? Gastroenterology 1998;114:842-45.
  25. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
  26. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.
  27. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steato-hepatitis. Hepatology 2002;35:898-904.
  28. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705-25.
  29. Fracanzani AL, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-98.
  30. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis 2012;16(3):567-85.
  31. Palmentieri B. et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-9.
  32. Mottin CC, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-7.
  33. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
  34. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
  35. Ratziu V, Giral P, Charlotte F, et al. Liver fibro sis in overweight patients. Gastroenterology 2000;118(6):1117-23.
  36. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1): 91-100.
  37. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84(5):1513-17.
  38. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
  39. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-47.
  40. Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28(4):519-24.
  41. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44(1): 27-33.
  42. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepati-tis: a multicenter validation study. Hepatology 2009;50(4):1072-78.
  43. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11(2):255-29.
  44. Santos VN, Leite-Mor MM, Kondo M, et al. Serum laminin, type IV collagen and hyaluro-nan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38(5): 747-53.
  45. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
  46. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47(2):455-60.
  47. Nobili V, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric nonalcoholic fatty liver disease. Gastroenterology 2009;136(1):160-57.
  48. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704-13.
  49. Tamura, Y. et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-96.
  50. Sjstr m, L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
  51. Chavez-Tapia NC, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD007340. doi: 10.1002/14651858. CD007340. pub2, 2010.
  52. Musso G, Gambino R, Cassader M, et al. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
  53. Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-80.
  54. Aithal GP, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.
  55. Belfort R, et al. A placebo-controlled trial of pio-glitazone in subjects with nonalcoholic steato-hepatitis. N Engl J Med 2006;355:2297-307.
  56. Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
  57. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
  58. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007;298:1180-88.
  59. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
  60. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis JAMA 2007;297(8):842-57. Review. Erratum in: JAMA 2008;299(7):765-66.
  61. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011;306:1549-56.
  62. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-92.
  63. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5.
  64. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005;41:690-5.
  65. Lewis JH, Mortensen ME, Zweig S, et al. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double blind, placebocontrolled, multicenter trial. Hepatology 2007;46(5):1453-63.
  66. Horlander JC, Kwo PY, Cummings OW, et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120(Suppl.):2767.
  67. Gomer-Dominguez E, Gisbert JP, Moreno-Monteagudo A, et al. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-47.
  68. Antonopoulos S, Mikros S, Mylonopoulos M, et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184: 233-34.
  69. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2011;106:71-7.
  70. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й выпуск// Сахарный диабет 2011. № 3 (приложение).
  71. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad Med 2010;122:16-27.
  72. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50(4):253-65.
  73. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5 мг, 5 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от 30.03.2012.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##